Adjuvant modulation of the immune responses and the outcome of infection with Chlamydia pneumoniae

Clinical and Experimental Immunology

Volumn 130, Issue 3, 2002, Pages 393-403

  Bandholtz, L ^a   Kreuger, M R ^b,c   Svanholm, C ^a   Wigzell, H ^a   Rottenberg, Martín E ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSIDADE DO VALE DO ITAJAÍ   (Brazil)

Author keywords

Adjuvant; Chlamydia pneumoniae; IL 10; Interferon; Vaccine

Indexed keywords

ANTIGEN; BACTERIAL PROTEIN; BACTERIAL VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 10; OLIGODEOXYNUCLEOTIDE; OUTER MAJOR PROTEIN 2; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL INFECTION; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; EMULSION; EXPRESSION VECTOR; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION SENSITIVITY; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CHAPERONIN 60; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CYTOKINES; LUNG; MICE; MICE, INBRED C57BL; PNEUMONIA, BACTERIAL; TH1 CELLS; VACCINES, DNA;

EID: 18744383028     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.02007.x     Document Type: Article

References (63)

1. Schnare M, Holt AC, Takeda K et al. Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Curr Biol 2000; 10:1139-42.
2. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-5.
3. Krieg AM, Yi AK, Schorr J et al. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol 1998; 6:23-7.
4. Sun S, Kishimoto H, Sprent J. DNA as an adjuvant: Capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. J Exp Med 1998; 187:1145-50.
5. Donnelly JJ, Ulmer JB, Shiver JW et al. DNA Vaccines Annu Rev Immunol 1997; 15:617-48.
6. Kuo CC, Jackson LA, Campbell LA et al. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 1995; 8:451-61.
7. Perry LL, Feilzer K, Caldwell HD. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways. J Immunol 1997; 158:3344-52.
8. Rottenberg M, Gigliotti Rothfuchs AC, Gigliotti D et al. Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice. J Immunol 1999, 2829-36.
9. Williams DM, Grubbs BG, Pack E et al. Humoral and cellular immunity in secondary infection due to murine Chlamydia trachomatis. Infect Immun 1997; 65:2876-82.
10. Johansson M, Schon K, Ward M et al. Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response. Infect Immun 1997; 65:1032-44.
11. Starnbach MN, Bevan MJ, Lampe MF. Protective cytotoxic T lymphocytes are induced during murine infection with Chlamydia trachomatis. J Immunol 1994; 153:5183-9.
12. Igietseme JU, Black CM, Caldwell HD. Chlamydia vaccines: Strategies and status. Biodrugs 2002; 16:19-35.
13. Zhang D, Yang X, Berry J et al. DNA vaccination with the major outer-membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection. J Infect Dis 1997; 176:1035-40.
14. Murdin AD, Dunn P, Sodoyer R et al. Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection. J Infect Dis 2000; 181 (Suppl. 3):S544-51.
15. Svanholm C, Bandholtz L, Castanos-Velez E et al. Protective DNA immunization against Chlamydia pneumoniae. Scand J Immunol 2000; 51:345-53.
16. Penttila T, Vuola JM, Puurula V et al. Immunity to Chlamydia pneumoniae induced by vaccination with DNA vectors expressing a cytoplasmic protein (Hsp60) or outer membrane proteins (MOMP and Omp2). Vaccine 2000; 19:1256-65.
17. Pal S, Barnhart KM, Wei Q et al. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine 1999; 17:459-65.
18. Igietseme JU, Murdin A. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes. Infect Immun 2000; 68:6798-806.
19. Pal S, Theodor I, Peterson EM et al. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge. Infect Immun 1997; 65:3361-9.
20. Su H, Messer R, Whitmire W et al. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. J Exp Med 1998; 188:809-18.
21. Watson MW, Lambden PR, Everson JS et al. Immunoreactivity of the 60 kDa cysteine-rich proteins of Chlamydia trachomatis, Chlamydia psittaci and Chlamydia pneumoniae expressed in Escherichia coli. Microbiology 1994; 140:2003-11.
22. Mygind P, Christiansen G, Persson K et al. Analysis of the humoral immune response to chlamydia outer membrane protein 2. Clin Diagn Lab Immunol 1998; 5:313-8.
23. Pal S, Fielder TJ, Peterson EM et al. Analysis of the immune response in mice following intrauterine infection with the Chlamydia trachomatis mouse pneumonitis biovar. Infect Immun 1993; 61:772-6.
24. Beatty PR, Stephens RS. Identification of Chlamydia trachomatis antigens by use of murine T cell lines. Infect Immun 1992; 60:4598-603.
25. LaVallie ER, Lu Z, Diblasio-Smith EA et al. Thioredoxin as a fusion partner for production of soluble recombinant proteins in Escherichia coli. Meth Enzymol 2000; 326:322-40.
26. LaVallie ER, DiBlasio EA, Kovacic S et al. A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. Biotechnology (NY) 1993; 11:187-93.
27. Nygren P, Eliasson M, Abrahamsen L et al. Analysis and use of serum albumin binding domains of streptococcal protein G. J Mol Recognit 1998; 1:69-76.
28. Svanholm C, Bandholtz L, Lobell A et al. Enhnacement of antibody responses by DNA immunization using expression vectors mediating efficient antigen presentation. J Immunol Meth 1999; 228:121-30.
29. Rahemtulla A, Fung-Leung WP, Schilham MW et al. Normal development and function of CD8+ cells but markedly decreased helper activity in mice lacking CD4. Nature 1991; 353:180-4.
30. Fung-Leung WP, Schilham MW, Rahemtulla A et al. CD8 is needed for the development of cytotoxic T cells but not helper T cells. Cell 1991; 65:443-9.
31. Mombaerts P, Iacomini J, Johnson R et al. RAG-1 deficient mice have no mature T and B lymphocytes. Cell 1992; 68:869-77.
32. Kuhn R, Lohler J, Rennick D et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263-74.
33. Schilham MW, Fung-Leung WP, Rahemtulla A et al. Alloreactive cyotoxic T cells can develop in mice lacking both CD4 and CD8. Eur J Immunol 1993; 23:1299-304.
34. Rottenberg M, Castaños-Velez E, Mesquita R et al. Intracellular colocalization of inducible nitric oxide synthase and Trypanosoma cruzi: Evidence for a dual pathway of iNOS induction. Eur J Immunol 1996; 26:3203-13.
35. Siebert PD, Larrick JW. Competitive PCR. Nature 1992; 359:557-9.
36. Lipford GB, Bauer M, Blank C et al. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants. Eur J Immunol 1997; 27:2340-4.
37. Davis HL, Weeranta R, Waldschmidt TJ et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998; 160:870-6.
38. Roman M, Martin-Orozco E, Goodman JS et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3:849-54.
39. Stacey KJ, Blackwell JM. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 1999; 67:3719-26.
40. Lindblad EB, Elhay MJ, Silva R et al. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 1997; 65:623-9.
41. Morrison RP, Lyng K, Caldwell HD. Chlamydial disease pathogenesis. Ocular hypersensitivity elicited by a genus-specific 57-kD protein. J Exp Med 1989; 169:663-75.
42. Goodall JC, Beacock-Sharp H, Deane KH et al. Recognition of the 60 kilodalton cysteine-rich outer membrane protein OMP2 by CD4 (+) T cells from humans infected with Chlamydia trachomatis. Clin Exp Immunol 2001; 126:488-93.
43. Kinnunen A, Paavonen J, Surcel HM. Heat shock protein 60 specific T cell response in chlamydial infections. Scand J Immunol 2001; 54:76-81.
44. Wolf K, Fischer E, Mead D et al. Chlamydia pneumoniae major outer membrane protein is a surface-exposed antigen that elicits antibodies primarily directed against conformation-dependent determinants. Infect Immun 2001; 69:3082-91.
45. Bachmaier K, Neu N, de la Maza LM et al. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999; 283:1335-9.
46. Boyle JS, Brady JL, Lew AM. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 1998; 392:408-11.
47. Rottenberg ME, Gigliotti Rothfuchs A, Gigliotti D et al. Regulation and role of IFN-gamma in the innate resistance to infection with Chlamydia pneumoniae. J Immunol 2000; 164:4812-8.
48. Yip HC, Karulin AY, Tary-Lehmann M et al. Adjuvant-guided type-1 and type-2 immunity: Infectious/noninfectious dichotomy defines the class of response. J Immunol 1999;162:3942-9.
49. Victoratos P, Yiangou M, Avramidis N et al. Regulation of cytokine gene expression by adjuvants in vivo. Clin Exp Immunol 1997; 109:569-78.
50. Moureau C, Vidal PL, Bennasser Y et al. Characterization of humoral and cellular immune responses in mice induced by immunization with HIV-1 Nef regulatory protein encapsulated in poly (DL-lactide-co-glycolide) microparticles. Mol Immunol 2002; 38:607-18.
51. Maron R, Hancock WW, Slavin A et al. Genetic susceptibility or resistance to autoimmune encephalomyelitis in MHC congenic mice is associated with differential production of pro- and anti-inflammatory cytokines. Int Immunol 1999; 11:1573-80.
52. Holland MJ, Harcus YM, Riches PL et al. Proteins secreted by the parasitic nematode Nippostrongylus brasiliensis act as adjuvants for Th2 responses. Eur J Immunol 2000;30:1977-87.
53. Comoy EE, Capron A, Thyphronitis G. Adjuvant is the major parameter influencing the isotype profiles generated during immunization with a protein antigen, the Schistosoma mansoni Sm28-GST. Scand J Immunol 1998; 47:444-52.
54. Comoy EE, Pestel J, Duez C et al. The house dust mite allergen, Dermatophagoides pteronyssinus, promotes type 2 responses by modulating the balance between IL-4 and IFN-gamma. J Immunol 1998; 160:2456-62.
55. Brewer JM, Conacher M, Satoskar A et al. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996; 26:2062-6.
56. Locksley R, Reiner S, Hatam F et al. Helper T cells without CD4. Control of Leishmaniasis in CD4 deficient mice. Science 1993; 261:1448-50.
57. Yang X, HayGlass KT, Brunham RC. Genetically determined differences in IL-10 and IFN-gamma responses correlate with clearance of Chlamydia trachomatis mouse pneumonitis infection. J Immunol 1996; 156:4338-44.
58. Cohen CR, Plummer FA, Mugo N et al. Increased interleukin-10 in the the endocervical secretions of women with non-ulcerative sexually transmitted diseases: A mechanism for enhanced HIV-1 transmission? Aids 1999; 13:327-32.
59. Yang X, Gartner J, Zhu L et al. IL-10 gene knockout mice show enhanced Th1-like protective immunity and absent granuloma formation following Chlamydia trachomatis lung infection. J Immunol 1999; 162:1010-7.
60. Igietseme JU, Ananaba GA, Bolier J et al. Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: Potential for cellular vaccine development. J Immunol 2000; 164:4212-9.
61. Mygind P, Christiansen G, Birkelund S. Topological analysis of Chlamydia trachomatis L2 outer membrane protein 2. J Bacteriol 1998; 180:5784-7.
62. Zhang DJ, Yang X, Shen C et al. Characterization of immune responses following intramuscular DNA immunization with the MOMP gene of Chlamydia trachomatis mouse pneumonitis strain. Immunology 1999; 96:314-21.
63. Shaw J, Grund V, Durling L et al. Dendritic cells pulsed with a recombinant chlamydial major outer membrane protein antigen elicit a CD4 (+) type 2 rather than type 1 immune response that is not protective. Infect Immun 2002;70:1097-105.